Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BURAN study of buparlisib (AN2025) plus paclitaxel versus paclitaxel alone in recurrent or metastatic head and neck squamous cell carcinoma
CTR20202685Phase 3Active
- Sponsor
- Adlai Nortye
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of buparlisib, paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by Adlai Nortye. Started Apr 2021; status: active.
02
Drugs
buparlisibpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20202685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202685.